文献速递胸部肿瘤

度伐利尤单抗对比化疗一线治疗肿瘤PD-L1表达25%或以上的转移性非小细胞肺癌:随机3期PEARL研究结果

Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
PubMed 文献 · J Thorac Oncol · 2024-11-07

PEARL研究纳入669例EGFR/ALK野生型、PD-L1肿瘤细胞表达≥25%的转移性非小细胞肺癌患者,随机接受度伐利尤单抗或化疗。度伐利尤单抗组死亡风险数值下降(OS HR=0.84,95%CI 0.71-0.99,p=0.037),但研究结论为未达统计学显著改善;低早期死亡风险人群OS HR=0.96(95%CI 0.79-1.15,p=0.628)。

要点

  • PD-L1≥25%人群度伐利尤单抗对比化疗OS HR=0.84(95%CI 0.71-0.99),中位OS 14.6个月 vs 12.8个月。
  • 低早期死亡风险且PD-L1≥25%人群OS HR=0.96(95%CI 0.79-1.15,p=0.628),中位OS 14.6个月 vs 15.0个月。
  • 3/4级治疗相关不良事件发生率度伐利尤单抗组15.5%,化疗组45.9%。

核心结论

  • 度伐利尤单抗对比化疗一线治疗PD-L1肿瘤细胞表达≥25%的转移性非小细胞肺癌未达统计学显著OS改善。
  • 度伐利尤单抗组OS的数值改善与既往一线免疫检查点抑制剂单药研究结果一致。

研究设计与样本

  • PEARL(NCT03003962)为开放标签3期研究,比较度伐利尤单抗单药与化疗一线治疗转移性非小细胞肺癌(EGFR/ALK野生型)。
  • 共669例既往未治疗的IV期转移性非小细胞肺癌成人患者按1:1随机分配。
  • 度伐利尤单抗20 mg/kg每四周一次;化疗每三周一次,共四至六个周期。
  • 双主要终点为PD-L1肿瘤细胞表达≥25%人群的OS和PD-L1≥25%且低早期死亡风险人群的OS。

主要发现

  • PD-L1≥25%人群:度伐利尤单抗组对比化疗组OS HR=0.84(95%CI 0.71-0.99,p=0.037),中位OS 14.6个月(95%CI 12.2-16.9)vs 12.8个月(95%CI 10.1-14.7)。
  • PD-L1≥25%且低早期死亡风险人群:度伐利尤单抗组对比化疗组OS HR=0.96(95%CI 0.79-1.15,p=0.628),中位OS 14.6个月(95%CI 12.6-17.2)vs 15.0个月(95%CI 13.1-16.8)。
  • 安全性人群中,3级或4级治疗相关不良事件发生率度伐利尤单抗组为15.5%,化疗组为45.9%。

关键数值与推荐

  • PD-L1≥25%人群度伐利尤单抗对比化疗OS HR=0.84(95%CI 0.71-0.99,p=0.037)。
  • PD-L1≥25%且低早期死亡风险人群度伐利尤单抗对比化疗OS HR=0.96(95%CI 0.79-1.15,p=0.628)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [EGFR/ALK wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL. METHODS: Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles. The dual primary endpoints were overall survival (OS) in the population with PD-L1 TC of 25% or higher and OS in the population at low risk of early mortality (LREM) with PD-L1 TC of 25% or higher. RESULTS: Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the 25% and higher PD-L1 TC population (OS hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.71-0.99, p = 0.037; median OS 14.6 months, 95% CI: 12.2-16.9 versus 12.8 months, 95% CI: 10.1-14.7, respectively). In the 25% and higher PD-L1 TC low risk of early mortality population the OS hazard ratio for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79-1.15, p = 0.628); median OS 14.6 months (95% CI: 12.6-17.2) versus 15.0 months (95% CI: 13.1-16.8), respectively. In the safety population, the incidence of grade 3 or 4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy). CONCLUSIONS: Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and 25% and higher PD-L1 TC. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lu S, Wu L, Wang Q, et al. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. J Thorac Oncol. 2024. PMID: 39521433. doi:10.1016/j.jtho.2024.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。